Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last Decade

Inflammatory properties are known to promote tumor progression leading to an impaired median overall survival (mOS). Various small studies have focused on a wide range of inflammation-based prognostic indicators. By using sufficient data from 1294 out of 2323 patients diagnosed with pancreatic cancer between 2009 and 2021 at our cancer center, inflammatory markers such as the neutrophil to lymphocyte ratio (NRL), the platelet to lymphocyte ratio (PLR), the lymphocyte to monocyte ratio (LMR) and the CRP to albumin ratio (CAR) were evaluated. We identified a new combined score, termed the inflammatory benchmark index (IBI). We performed univariate and multivariate overall survival analyses and identified optimal prognostic cut-off values for each parameter. In univariate analyses, advanced age ( < 0.001), gender ( < 0.001), tumor stage ( < 0.001), CA19-9 ( = 0.001), NLR ( = 0.001), LMR ( = 0.004), PLR ( = 0.004), CAR ( = 0.001) and IBI ( = 0.001) were identified as prognostic markers. In multivariate analyses advanced age ( < 0.001), gender ( = 0.001), tumor stage ( < 0.001), CA19-9 ( < 0.001), NLR ( = 0.001), LMR ( = 0.038), CAR ( < 0.001) and IBI ( < 0.001) were independent prognostic markers. These findings emphasize the impact of inflammation in pancreatic cancer, provide easily accessible prognostic values for the clinician, and may be useful as stratification parameters for trials aimed at patient inflammation or immune response.